Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab monotherapy for bone disease in RRMM (REBUILD)
NCT03475628Phase 2Unknown
- Sponsor
- Hellenic Society of Hematology
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03475628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475628.